Journal article icon

Journal article

Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer

Abstract:

Purpose: The cancer esophagus gefitinib (COG) trial demonstrated improved progression free survival with the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib relative to placebo in advanced esophageal cancer patients with disease progression after chemotherapy. Rapid and durable responses were observed in a minority. We hypothesised that genetic aberration of the EGFR pathway would identify patients benefitting from gefitinib.

Patients and Methods...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1200/JCO.2016.70.3934

Authors


More by this author
Institution:
University of Oxford
Department:
St Johns College
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS, CSM
Role:
Author
More from this funder
Grant:
Chief Scientists Office (grant number ETM/116)
Grampian Gastro-esophageal Cancer Research Fund More from this funder
Publisher:
American Society of Clinical Oncology Publisher's website
Journal:
Journal of Clinical Oncology Journal website
Volume:
35
Issue:
20
Pages:
2279-2287
Publication date:
2017-05-24
Acceptance date:
2017-03-28
DOI:
EISSN:
1527-7755
ISSN:
0732-183X
Pubs id:
pubs:687763
URN:
uri:8983c31d-8bc0-43a4-a5dd-3962c6c478ed
UUID:
uuid:8983c31d-8bc0-43a4-a5dd-3962c6c478ed
Local pid:
pubs:687763
Paper number:
20

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP